{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:50:36Z","timestamp":1648986636044},"reference-count":47,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/naika.102.1105","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T23:12:41Z","timestamp":1399677161000},"page":"1105-1113","source":"Crossref","is-referenced-by-count":0,"title":["1. Pathogenesis and Management of Minimal Change Nephrotic Syndrome"],"prefix":"10.2169","volume":"102","author":[{"given":"Kazuhiko","family":"Tsuruya","sequence":"first","affiliation":[{"name":"Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Fujimoto S, et al: Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 17: 687-692, 1991.","DOI":"10.1016\/S0272-6386(12)80353-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nakayama M, et al: Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 39: 503-512, 2002.","DOI":"10.1053\/ajkd.2002.31400"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Takei T, et al: The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clin Exp Nephrol 11: 214-217, 2007.","DOI":"10.1007\/s10157-007-0484-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Waldman M, et al: Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2: 445-453, 2007.","DOI":"10.2215\/CJN.03531006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nolasco F, et al: Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 29: 1215-1223, 1986.","DOI":"10.1038\/ki.1986.130"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Shalhoub RJ: Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2 (7880): 556-560, 1974.","DOI":"10.1016\/S0140-6736(74)91880-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yap HK, et al: Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10: 529-537, 1999.","DOI":"10.1681\/ASN.V103529"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Lai KW, et al: Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 18: 1476-1485, 2007.","DOI":"10.1681\/ASN.2006070710"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Reiser J, et al: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113: 1390-1397, 2004.","DOI":"10.1172\/JCI20402"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Garin EH, et al: Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20: 260-266, 2009.","DOI":"10.1681\/ASN.2007080836"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Garin EH, et al: Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78: 296-302, 2010.","DOI":"10.1038\/ki.2010.143"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shimada M, et al: Minimal change disease: a "two-hit" podocyte immune disorder? Pediatr Nephrol 26: 645-649, 2011.","DOI":"10.1007\/s00467-010-1676-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Clement LC, et al: Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17: 117-122, 2011.","DOI":"10.1038\/nm.2261"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Black DA, et al: Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 3: 421-426, 1970.","DOI":"10.1136\/bmj.3.5720.421"},{"key":"15","unstructured":"15) Coggins CH: Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. Trans Am Clin Climatol Assoc 97: 18-26, 1986."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tse KC, et al: Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 18: 1316-1320, 2003.","DOI":"10.1093\/ndt\/gfg134"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mak SK, et al: Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 11: 2192-2201, 1996.","DOI":"10.1093\/oxfordjournals.ndt.a027136"},{"key":"18"},{"key":"19"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Fukudome K, et al: Comparison of the effects of intravenous methylprednisolone pulse versus oral prednisolone therapies on the first attack of minimal-change nephrotic syndrome in adults. Nephrology (Carlton) 17: 263-268, 2012.","DOI":"10.1111\/j.1440-1797.2011.01544.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Eguchi A, et al: Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant 25: 124-129, 2010.","DOI":"10.1093\/ndt\/gfp422"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Faul C, et al: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008.","DOI":"10.1038\/nm.1857"},{"key":"23","unstructured":"23) Ponticelli C, et al: Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 8: 1326-1332, 1993."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Cattran DC, et al: Kidney Int 72: 1429-1447, 2007.","DOI":"10.1038\/sj.ki.5002553"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yoshioka K, et al: A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58: 317-324, 2000.","DOI":"10.1046\/j.1523-1755.2000.00168.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hodson EM, et al: Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev 1: CD002290, 2008.","DOI":"10.1002\/14651858.CD002290.pub3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kawasaki Y, et al: Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome. Nephrol Dial Transplant 20: 2243-2247, 2005.","DOI":"10.1093\/ndt\/gfh996"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ohtomo Y, et al: High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol 20: 1744-1749, 2005.","DOI":"10.1007\/s00467-005-2025-3"},{"key":"29"},{"key":"30","unstructured":"30) Kawasaki Y, et al: Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol 20: 52-56, 2007."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Fujieda M, et al: Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 69: 179-184, 2008.","DOI":"10.5414\/CNP69179"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Fujinaga S, et al: Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol 26: 479-483, 2011.","DOI":"10.1007\/s00467-010-1707-7"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Gilbert RD, et al: Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21: 1698-1700, 2006.","DOI":"10.1007\/s00467-006-0228-x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Smith GC: Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 22: 893-898, 2007.","DOI":"10.1007\/s00467-006-0427-5"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hofstra JM, et al: Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant 22: 2100-2102, 2007.","DOI":"10.1093\/ndt\/gfm128"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Fran\u00e7ois H, et al: Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 49: 158-161, 2007.","DOI":"10.1053\/j.ajkd.2006.10.015"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Guigonis V, et al: Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23: 1269-1279, 2008.","DOI":"10.1007\/s00467-008-0814-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Sawara Y, et al: Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 72: 69-72, 2009.","DOI":"10.5414\/CNP72069"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Fujinaga S, et al: Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 25: 539-544, 2010.","DOI":"10.1007\/s00467-009-1377-5"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Ito S, et al:Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 2012 Oct 10.[Epub ahead of print].","DOI":"10.1007\/s00467-012-2319-1"},{"key":"41","unstructured":"41) Takei T, et al: Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant 2012 Dec 13.[Epub ahead of print]."},{"key":"42"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) International Study of Kidney Disease in Children: Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 20: 765-771, 1981.","DOI":"10.1038\/ki.1981.209"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Bagga A, et al: Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356: 2751-2752, 2007.","DOI":"10.1056\/NEJMc063706"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Yang T, et al: Rapid remission of steroid and mycophenolate mofetil (mmf) -resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 23: 377-380, 2008.","DOI":"10.1093\/ndt\/gfm592"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Kurosu N, et al: Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med 48: 1901-1904, 2009.","DOI":"10.2169\/internalmedicine.48.2435"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Muso E, et al; Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group: Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89: 408-415, 2001.","DOI":"10.1159\/000046112"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/5\/102_1105\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:23:00Z","timestamp":1648984980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/5\/102_1105\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.102.1105","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}